Zymeworks (ZYME) announced that the first patient has been dosed in the company’s first-in-human Phase 1 trial to evaluate the safety and tolerability of the investigational therapy ZW191 in the treatment of advanced folate receptor-expressing solid tumors including ovarian, endometrial, and non-small cell lung cancers.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks price target raised to $18 from $16 at Citi
- Zymeworks’ Future Hinges on Developing Key Diagnostic Tests Amidst Regulatory Challenges
- PayPal, Estee Lauder downgraded: Wall Street’s top analyst calls
- Wells downgrades Zymeworks with zanidatamab approval priced in
- Zymeworks downgraded to Equal Weight from Overweight at Wells Fargo